The proof is in the pudding: patient engagement in studying cannabidiol in mild cognitive impairment

Abstract Background Patient engagement (PE) in clinical trials has gained importance yet remains uncommon, particularly in patients with mild cognitive impairment (MCI), a critical precursor to Alzheimer’s disease (AD). Cannabidiol (CBD) shows potential in slowing MCI progression due to its neuropro...

תיאור מלא

מידע ביבליוגרפי
Main Authors: Antonia Keck, Julia-Sophia Scheuermann, Petra Scheerbaum, Elmar Graessel, Kirsten R. Müller-Vahl
פורמט: Article
שפה:English
יצא לאור: BMC 2025-01-01
סדרה:BMC Complementary Medicine and Therapies
נושאים:
גישה מקוונת:https://doi.org/10.1186/s12906-025-04753-w